A systematic review of oral methotrexate for multiple sclerosis
- 1 August 2006
- journal article
- review article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 12 (4) , 507-510
Abstract
Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only. This trial reported a non-significant reduction in sustained Expanded Disability Status Scale (EDSS) progression and number of relapses in favour of methotrexate therapy. There were no data on relapse rate and no difference in time to first relapse. Minor side-effects were reported in both methotrexate (87.1%) and placebo groups (89.7%), but there were no major side-effects. Further trials are required in both relapsing-remitting and progressive groups to establish the role of oral methotrexate in MS.Keywords
This publication has 10 references indexed in Scilit:
- The initiation of the autoimmune response in multiple sclerosisClinical Neurology and Neurosurgery, 2004
- Methotrexate hepatotoxicity: What is the evidence?Inflammation Research, 1998
- Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisAnnals of Neurology, 1995
- The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.Journal of Clinical Investigation, 1993
- Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- Possible role of histamine in pathogenesis of autoimmune diseases: Implications for immunotherapy with histamine-2 receptor antagonistsMedical Hypotheses, 1992
- Acute and chronic suppression of leukotriene B4 synthesis EX vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexateArthritis & Rheumatism, 1992
- Methotrexate: Mechanism of action in rheumatoid arthritisSeminars in Arthritis and Rheumatism, 1990
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983